Page 1,836«..1020..1,8351,8361,8371,838..1,8501,860..»

'Stem cell' test could identify most aggressive breast cancers

Posted: March 10, 2015 at 2:40 am

Testing breast cancer cells for how closely they resemble stem cells could identify women with the most aggressive disease, a new study suggests.

Researchers found that breast cancers with a similar pattern of gene activity to that of adult stem cells had a high chance of spreading to other parts of the body.

Assessing a breast cancer's pattern of activity in these stem cell genes has the potential to identify women who might need intensive treatment to prevent their disease recurring or spreading, the researchers said.

Adult stem cells are healthy cells within the body which have not specialised into any particular type, and so retain the ability to keep on dividing and replacing worn out cells in parts of the body such as the gut, skin or breast.

A research team from The Institute of Cancer Research, London, King's College London and Cardiff University's European Cancer Stem Cell Research Institute identified a set of 323 genes whose activity was turned up to high levels in normal breast stem cells in mice.

The study is published today (Wednesday) in the journal Breast Cancer Research, and was funded by a range of organisations including the Medical Research Council, The Institute of Cancer Research (ICR), Breakthrough Breast Cancer and Cancer Research UK.

The scientists cross-referenced their panel of normal stem cell genes against the genetic profiles of tumours from 579 women with triple-negative breast cancer - a form of the disease which is particularly difficult to treat.

They split the tumour samples into two categories based on their 'score' for the activity of the stem cell genes.

Women with triple-negative tumours in the highest-scoring category were much less likely to stay free of breast cancer than those with the lowest-scoring tumours. Women with tumours from the higher-scoring group had around a 10 per cent chance of avoiding relapse after 10 years, while women from the low-scoring group had a chance of around 60 per cent of avoiding relapse.

The results show that the cells of aggressive triple-negative breast cancers are particularly 'stem-cell-like', taking on properties of stem cells such as self-renewal to help them grow and spread. They also suggest that some of the 323 genes could be promising targets for potential cancer drugs.

See more here:
'Stem cell' test could identify most aggressive breast cancers

Posted in Stem Cell Therapy | Comments Off on 'Stem cell' test could identify most aggressive breast cancers

New test uses human stem cells to identify dangerous side effects of drugs

Posted: March 9, 2015 at 2:53 pm

IMAGE:The new test uses endothelial cells grown from stem cells in the blood. This image shows these cells stained with fluorescent markers. view more

Credit: Imperial College London

Scientists at Imperial College London have developed a test that uses combinations of cells from a single donor's blood to predict whether a new drug will cause a severe immune reaction in humans.

The test could avert disasters like the 2006 trial of the drug TGN1412, which led to six healthy young men being admitted to intensive care with multiple organ failure. The volunteers receiving TGN1412 experienced a catastrophic inflammatory reaction called a cytokine storm.

Cytokine storm reactions are a particular worry for new biological therapies, or "biologics", which use biological material such as antibodies. Many blockbuster drugs such as the cancer drugs Herceptin and Avastin are biologics, as are around a third of medicines in the pharmaceutical pipeline. Because these medicines are specific to humans, they can cause severe reactions that don't materialise in animal studies, so tests on human cells are essential.

However, cytokine storm side effects are hard to predict with tests were just one cell type is used, since they depend on interactions between blood cells and endothelial cells, which form the lining of blood vessels. But because endothelial cells are deep within the body, they are normally only grown from tissue removed in surgery or post mortem, or from umbilical vessels after birth.

Because of this, current tests use endothelial cells taken from vessels of one donor, and white blood cells from a different donor. When cells from two different donors are used, one may have an immune reaction to the other, meaning the system is already primed for inflammation before the drug is added. This can result in the test falsely showing a severe immune reaction to a drug that is safe.

Researchers at Imperial College London got around this problem by isolating stem cells from the blood of a volunteer, and using them to grow endothelial cells in a dish. They then took white blood cells which they added to the donor's own endothelial cells to recreate the unique conditions found in their blood vessels. When TGN1412 was added to the test tube, the mixture of cells released a cytokine storm, as would happen inside the body.

The new method is better as it only requires blood from one donor and doesn't mix cells from different people, with the advantage of making a more reliable test.

Professor Jane Mitchell, from the National Heart and Lung Institute at Imperial College London, who led the study, said: "As biological therapies become more mainstream, it's more likely that drugs being tested on humans for the first time will have unexpected and potentially catastrophic effects. We've used adult stem cell technology to develop a laboratory test that could prevent another disaster like the TGN1412 trial.

View original post here:
New test uses human stem cells to identify dangerous side effects of drugs

Posted in Stem Cells | Comments Off on New test uses human stem cells to identify dangerous side effects of drugs

Researchers engineer wisdom teeth stem cells to treat corneal scarring

Posted: March 9, 2015 at 2:53 pm

Published February 23, 2015

Corneal disease causes nearly 10 percent of blindness cases worldwide, and the condition is typically treated with donor corneas. But researchers at the University of Pittsburgh have discovered that stem cells from the dental pulp of wisdom teeth can be manipulated to form cells of the eyes cornea a finding that may provide an easier procedure to repair corneal scarring.

In the study, published Monday in the journal STEM CELLS Translational Medicine, ophthalmologists turned dental pulp from a routine third molar, or wisdom tooth, into corneal stromal cells called keratocytes, which have the same embryonic origin.

According to a news release, study authors injected the altered keratocytes into the corneas of healthy mice. Researchers also took the cells and created constructs of corneal stroma akin to natural tissue. Previous studies have found that dental pulp stem cells can be reused for neural, bone and other cells, which suggests they have potential for regenerative therapies, lead author Fatima Syed-Picard, an ophthalmology professor at the University of Pittsburgh, said in the news release.

Next, researchers plan to study whether the method can fix corneal scarring in animals.

Senior investigator James Funderburgh, also an ophthalmology professor at the University of Pittsburgh, noted that shortages of donor corneas or potential rejections of donor tissues sometimes occur, and those problems can result in permanent vision loss.

"Our work is promising, Funderburgh said, because using the patient's own cells for treatment could help us avoid these problems."

More here:
Researchers engineer wisdom teeth stem cells to treat corneal scarring

Posted in Stem Cells | Comments Off on Researchers engineer wisdom teeth stem cells to treat corneal scarring

Order matters: Sequence of genetic mutations determines how cancer behaves

Posted: March 9, 2015 at 2:51 pm

The order in which genetic mutations are acquired determines how an individual cancer behaves, according to research from the University of Cambridge, published today in the New England Journal of Medicine.

Most of the genetic mutations that cause cancer result from environmental 'damage' (for example, through smoking or as a result of over-exposure to sunlight) or from spontaneous errors as cells divide. In a study published today, researchers at the Department of Haematology, the Cambridge Institute for Medical Research and the Wellcome Trust/Medical Research Council Stem Cell Institute show for the first time that the order in which such mutations occur can have an impact on disease severity and response to therapy.

The researchers examined genetically distinct single stem cells taken from patients with myeloproliferative neoplasms (MPNs), a group of bone marrow disorders that are characterised by the over-production of mature blood cells together with an increased risk of both blood clots and leukaemia. These disorders are identified at a much earlier stage than most cancers because the increased number of blood cells is readily detectable in blood counts taken during routine clinical check-ups for completely different problems.

Approximately one in ten of MPN patients carry mutations in both the JAK2 gene and the TET2 gene. By studying these individuals, the research team was able to determine which mutation came first and to study the effect of mutation order on the behaviour of single blood stem cells.

Using samples collected primarily from patients attending Addenbrooke's Hospital, part of the Cambridge University Hospitals, researchers showed that patients who acquire mutations in JAK2 prior to those in TET2 display aberrant blood counts over a decade earlier, are more likely to develop a more severe red blood cell disease subtype, are more likely to suffer a blood clot, and their cells respond differently to drugs that inhibit JAK2.

Dr David Kent, one of the study's lead authors, says: "This surprising finding could help us offer more accurate prognoses to MPN patients based on their mutation order and tailor potential therapies towards them. For example, our results predict that targeted JAK2 therapy would be more effective in patients with one mutation order but not the other."

Professor Tony Green, who led the study, adds: "This is the first time that mutation order has been shown to affect any cancer, and it is likely that this phenomenon occurs in many types of malignancy. These results show how study of the MPNs provides unparalleled access to the earliest stages of tumour development (inaccessible in other cancers, which usually cannot be detected until many mutations have accumulated). This should give us powerful insights into the origins of cancer."

Work in the Green Lab is supported in party by Leukaemia and Lymphoma Research and Cancer Research UK.

Dr Matt Kaiser, Head of Research at Leukaemia & Lymphoma Research, said: "We are becoming more and more aware that a cancer's genetic signature can vary from patient to patient, and we are becoming better at personalising treatment to match this. The discovery that the order in which genetic errors occur can have such a big impact on cancer progression adds an important extra layer of complexity that will help tailor treatment for patients with MPNs. The technology to do this sort of study has been available only recently and it shows once again how pioneering research into blood cancers can reveal fundamental insights into cancer in general."

Dr ine McCarthy, Science Information Officer at Cancer Research UK, says: "The methods used in this pioneering research could help improve our understanding of how cancer cells develop mutations and when they do so. This interesting study suggests that the order in which genetic faults appear can affect how patients respond to different drugs - this insight could help doctors personalise treatment to make it more effective for each patient."

See the original post:
Order matters: Sequence of genetic mutations determines how cancer behaves

Posted in Genetic medicine | Comments Off on Order matters: Sequence of genetic mutations determines how cancer behaves

Targazyme Inc. Receives Orphan Drug Designation to TZ101 for Use With Regulatory T Cells to Prevent & Reduce the …

Posted: March 9, 2015 at 2:47 pm

Orphan Designation Provides 7-Year Post Approval Marketing Exclusivity, Tax Credits and Elimination of FDA Prescription Drug User Fees

SAN DIEGO, CA--(Marketwired - February 10, 2015) - Targazyme Inc., a clinical-stage biopharmaceutical company developing enzyme technologies and products to improve efficacy outcomes for stem cell transplantation, immunotherapy, gene therapy and regenerative medicine, announced today that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug designation to TZ101 to prevent and reduce the severity and incidence of graft vs. host disease (GVHD) in patients eligible for hematologic stem cell transplant.

GVHD is a serious, life-threating complication of stem cell transplantation.Orphan drug status confirms the importance of Targazyme's novel treatment approach to prevent and reduce the incidence and severity of GVHD in patients with blood cancers where stem cell transplant is prescribed.TZ101 could potentially transform hematopoietic stem cell transplantation by reducing patient morbidity and mortality from GVHD, which occurs in a large percentage of these patients and is very difficult to manage clinically.

"Our work with TZ101 demonstrates impressive increases in the persistence and activity of regulatory T cells in preclinical models of GVHD," said Dr. Elizabeth J. Shpall, Deputy Chair of the Department of Stem Cell Transplantation and Cellular Therapy at The University of Texas MD Anderson Cancer Center."We are looking forward to beginning clinical trials on this promising modality for preventing GVHD in our patients undergoing stem cell transplantation."

Orphan Drug Designation by FDA confers financial benefits and incentives, such as potential Orphan Drug grant funding to defray the cost of clinical testing, tax credits for the cost of clinical research, a 7 year period of exclusive marketing after Approval and a Waiver of Prescription Drug User Fee Act (PDUFA) filing fees which are now greater than $2 million.

"The granting of Orphan Drug status for TZ101 for prevention of GVHD in stem cell transplant patients, as well as our previous Orphan Drug designation of TZ101 for cord blood transplantation, provides additional validation of our innovative platform technologies," said Lynnet Koh, Chairman & Chief Executive Officer of Targazyme."TZ101 and our second product, TZ102 are enabling technologies for improving efficacy outcomes for multiple cell-based therapeutic approaches used to prevent and treat a variety of different diseases for which there is a high unmet medical need.In addition to initiating our registration trial with TZ101 in hematopoietic stem cell transplantation, we plan to embark on our cancer immunotherapy trial later this year."

About Targazyme, Inc.

Targazyme Inc. is a San Diego-based, clinical-stage biopharmaceutical company developing novel enzyme-based platform technologies and products to improve clinical efficacy outcomes for stem cell medicine, auto-immunotherapy, gene therapy and regenerative medicine.

The company's clinical-grade fucosyltransferase enzymes and small molecule products (TZ101 and TZ102) are off-the-shelf products used at the point-of-care to treat therapeutic cells immediately before infusion into the patient using a simple procedure that is easily incorporated into existing medical practice.The company has received a number of world-wide patents, multiple FDA orphan drug designations and major medical/scientific awards and grants.

Targazyme has partnerships and collaborations with Kyowa Hakko Kirin and Florida Biologix, as well as various medical research institutions including The University of Texas MD Anderson Cancer Center, Oklahoma Medical Research Foundation, Texas Transplant Institute, Case Western/University Hospitals, Scripps Hospitals, Fred Hutchinson Cancer Research Center, UCLA Medical Center, Stanford University Medical Center, University of Minnesota Medical Center, University of California San Diego, Sanford-Burnham Medical Research Institute, Indiana University, Memorial Sloan Kettering Cancer Center, and New York Blood Center.For more information please go to http://www.targazyme.com.

The rest is here:
Targazyme Inc. Receives Orphan Drug Designation to TZ101 for Use With Regulatory T Cells to Prevent & Reduce the ...

Posted in Cell Medicine | Comments Off on Targazyme Inc. Receives Orphan Drug Designation to TZ101 for Use With Regulatory T Cells to Prevent & Reduce the …

Nature Cell Biology : Expansion of stem cells counteracts age-related mammary regression… – Video

Posted: March 8, 2015 at 11:40 pm


Nature Cell Biology : Expansion of stem cells counteracts age-related mammary regression...
Expansion of stem cells counteracts age-related mammary regression in compound Timp1/Timp3 null mice. Hartland W. Jackson et al (2015), Nature Cell Biology h...

By: KeSimpulan

Link:
Nature Cell Biology : Expansion of stem cells counteracts age-related mammary regression... - Video

Posted in Stem Cell Videos | Comments Off on Nature Cell Biology : Expansion of stem cells counteracts age-related mammary regression… – Video

Intestinal Stem Cells Part 7 – Video

Posted: March 8, 2015 at 11:40 pm


Intestinal Stem Cells Part 7
In this video we discuss the role of intestinal stem cells in the tissue renewal of the intestinal epithelium.

By: Ben Garside

Read this article:
Intestinal Stem Cells Part 7 - Video

Posted in Stem Cell Videos | Comments Off on Intestinal Stem Cells Part 7 – Video

First Steps in Making a Microfluidics Chip To Capture Cancer Stem Cells – Video

Posted: March 8, 2015 at 11:40 pm


First Steps in Making a Microfluidics Chip To Capture Cancer Stem Cells
Watch a little #39;Real Time #39; science in less than 60 seconds.

By: TumorGen MDx

Excerpt from:
First Steps in Making a Microfluidics Chip To Capture Cancer Stem Cells - Video

Posted in Stem Cell Videos | Comments Off on First Steps in Making a Microfluidics Chip To Capture Cancer Stem Cells – Video

Maintain healthy Stem Cells today with FINITI – TA65 by JEUNESSE 2.5 min video – Video

Posted: March 8, 2015 at 11:40 pm


Maintain healthy Stem Cells today with FINITI - TA65 by JEUNESSE 2.5 min video
FINITI (trademark) Contains the only known patented nutrient shown to lengthen short TELOMERES IN HUMANS.. Learn more and SHOP at http://www.albertobango.jeunesseglobal.com/ ..Stay Young ...

By: Alberto Bango

Excerpt from:
Maintain healthy Stem Cells today with FINITI - TA65 by JEUNESSE 2.5 min video - Video

Posted in Stem Cell Videos | Comments Off on Maintain healthy Stem Cells today with FINITI – TA65 by JEUNESSE 2.5 min video – Video

New York Blood Center's New Mobile App Helps Save Lives On the Go

Posted: March 8, 2015 at 10:55 pm

NEW YORK, March 5, 2015 /PRNewswire-USNewswire/ -- New York Blood Center (NYBC) recently launched a new mobile app providing a convenient, user friendly platform for blood donors to find donation locations, make and manage appointments, view donation history and donor profiles, and access the full NYBC website to manage Donor Advantage accounts, redeem points, and much more.

"With the launch of our new mobile app, we continue efforts to enhance the donation experience for the many blood donors who make such a profound difference in the lives of patients in need," said NYBC Executive Director of Donor Marketing Harvey Schaffler. "NYBC's app provides donors with the quick and easy convenience of mobile access to the most up-to-date donation information on the go and at their fingertips."

The app is available free of charge in the App Store for iPhone and Android. Search "NYBC" to download the app today.

To schedule a blood donation, visit http://www.nybloodcenter.org or call 1-800-933-2566 (BLOOD).

Forinformation about the Donor Advantage Program, please visit http://www.mydonoradvantage.com.

About New York Blood CenterNow celebrating its 50th anniversary, New York Blood Center (NYBC) is one of the largest independent, community-based blood centers in the country. Each year, NYBC provides approximately one million blood products to nearly 200 hospitals in the Northeast. NYBC also provides a wide array of transfusion-related medical services. NYBC is also home to the world's largest public cord blood bank, which provides stem cells for transplant in many countries, and a renowned research institute, which, among other milestones, developed the Hepatitis B vaccine and innovative blood purification technology. Please visit us on Facebook at http://www.facebook.com/newyorkbloodcenter.

Follow us on Twitter: @NY_BloodCenter. http://www.nybloodcenter.org

CONTACT: Harvey Schaffler, 516-478-5021

SOURCE New York Blood Center

Read this article:
New York Blood Center's New Mobile App Helps Save Lives On the Go

Posted in New York Stem Cells | Comments Off on New York Blood Center's New Mobile App Helps Save Lives On the Go

Page 1,836«..1020..1,8351,8361,8371,838..1,8501,860..»